DWTX Dogwood Therapeutics, Inc. - Common Stock
$2.14
价格 · 八月 18, 2026
截至...的财报数据 八月 14, 2026
52周区间
$1–$10
10% of range
分析师评级
BUY
8 analysts
目标价
$14
+554% upside
P/E (TTM)
-0.3
ROE
-83.8%
净利润率
—
DWTX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$2.14
市值
$64M
P/E (TTM)
-0.3
每股收益 (TTM)
$-7.13
营收 (TTM)
—
股息收益率
—
ROE
-83.8%
负债/权益
—
52周区间
$1 – $10
DWTX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
—
EPS
$-7.13
2020-12-31
→
2025-12-31
自由现金流
—
利润率
—
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
DWTX
同行中位数
P/E (TTM)
-0.3
—
P/B (市净率)
0.8
1.6
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
DWTX
同行中位数
ROA
-37.1%
-64.3%
ROE
-83.8%
-102.1%
ROIC
-37.6%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
DWTX
同行中位数
Current Ratio (流动比率)
2.8
4.8
Quick Ratio (速动比率)
2.1
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
DWTX
同行中位数
Revenue YoY (营收同比增长)
123.6%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
DWTX
同行中位数
DWTX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
8 位分析师
- 强烈买入 2 25.0%
- 买入 5 62.5%
- 持有 1 12.5%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
3 位分析师 · 2026-08-16
中位数
$15.00
平均值
$14.00
← 低于所有目标
$2.14
最低
$12.00
最高
$15.00
中位数目标
$15.00
+600.9%
平均目标
$14.00
+554.2%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-2.0%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年3月31日 | $-0.15 | $-0.26 | 0.11% |
| 2025年12月31日 | $-0.07 | $-1.18 | 1.1% |
| 2025年9月30日 | $-8.20 | $-1.25 | -7.0% |
| 2025年6月30日 | $-1.99 | $-1.94 | -0.05% |
| 2025年3月31日 | $-4.19 | $-2.42 | -1.8% |
| 2024年12月31日 | $-5.87 | $-1.44 | -4.4% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| DWTX | $124M | -0.6 | 123.6% | — | -83.8% | — |
| CYPH | $97M | 16.6 | — | — | 6.1% | — |
| NMAD | — | — | — | — | — | — |
| IBIO | $15M | -0.4 | 77.8% | -4594.2% | -101.5% | — |
| RNTX | — | -0.6 | — | — | — | — |
| CRDF | $192M | -4.1 | -13.2% | -7732.0% | -88.2% | — |
| SPRO | $131M | 15.5 | 39.2% | 12.8% | 18.7% | — |
| GOSS | $724M | -4.1 | -57.7% | -351.5% | 201.8% | — |
| CTOR | $170M | -6.0 | — | — | -61.5% | — |
| XBIT | — | -1.6 | — | — | — | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $22M | $4M | $2M | $8M | $11M | $194.0K | |
| SG&A Expense | $6M | $9M | $4M | $4M | $5M | $10M | |
| Operating Expenses | $28M | $12M | $5M | $12M | $16M | $10M | |
| Operating Income | $-28M | $-12M | $-5M | $-12M | $-16M | $-10M | |
| Other Non-op | $-6M | $-123.0K | $150.9K | $67.5K | $-319.3K | $-341.0K | |
| Pretax Income | $-34M | $-12M | $-5M | $-12M | $-16M | $-10M | |
| Income Tax | $221.1K | $-503 | · | · | · | · | |
| Net Income | $-34M | $-12M | $-5M | $-12M | $-16M | $-10M | |
| EPS (Basic) | $-7.13 | $-12.52 | $-7.05 | $-1.11 | $-1.92 | $-2.10 | |
| EPS (Diluted) | $-7.13 | $-12.52 | $-7.05 | $-1.11 | $-1.92 | $-2.10 | |
| Shares (Basic) | 4,977,446 | 1,027,788 | 751,071 | 11,070,116 | 8,329,310 | 4,926,985 | |
| Shares (Diluted) | 4,977,446 | 1,027,788 | 751,071 | 11,070,116 | 8,329,310 | 4,926,985 | |
| EBITDA | $-28M | $-12M | $-5M | $-12M | $-16M | · |
资产负债表 24
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7M | $15M | $3M | $7M | $14M | $30M | |
| Prepaid Expense | $2M | $2M | $848.5K | $1M | $2M | $2M | |
| Current Assets | $8M | $17M | $4M | $8M | $16M | $31M | |
| PP&E (Net) | $12.8K | $16.8K | · | · | · | · | |
| PP&E (Gross) | $12.8K | $18.4K | · | · | · | · | |
| Accum. Depreciation | · | $1.6K | · | · | · | · | |
| Goodwill | $12M | $12M | · | · | · | · | |
| Intangibles | $69M | $66M | · | · | · | · | |
| Total Assets | $90M | $94M | $4M | $8M | $16M | $31M | |
| Accounts Payable | $760.9K | $1M | $111.9K | $573.2K | $353.9K | $368.9K | |
| Accrued Liabilities | $2M | $2M | $246.6K | $470.1K | $921.8K | $784.1K | |
| Current Liabilities | $3M | $3M | $358.5K | $1M | $1M | $2M | |
| Capital Leases | $105.8K | $154.9K | · | · | · | · | |
| Deferred Tax | $12M | $11M | $0 | $340.9K | $390.0K | $428.4K | |
| Other Non-current Liabilities | · | $15M | · | · | · | · | |
| Total Liabilities | $15M | $30M | $358.5K | $1M | $1M | $2M | |
| Common Stock | $3.0K | $133 | $77 | $1.8K | $833 | $830 | |
| Paid-in Capital | $184M | $68M | $66M | $63M | $58M | $58M | |
| Retained Earnings | $-108M | $-74M | $-61M | $-56M | $-44M | $-28M | |
| Treasury Stock | $299.1K | $299.1K | $299.1K | · | · | · | |
| AOCI | $-587.0K | $-4M | · | · | · | · | |
| Stockholders' Equity | $75M | $-10M | $4M | $7M | $15M | $30M | |
| Liabilities + Equity | $90M | $94M | $4M | $8M | $16M | $31M | |
| Shares Outstanding | 29,743,516 | 1,332,178 | 770,317 | 18,330,390 | 8,330,390 | 8,305,075 |
现金流 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $355.6K | $476.0K | $620.0K | $582.7K | $322.9K | $7M | |
| Deferred Tax | $221.1K | $-503 | · | · | · | · | |
| Operating Cash Flow | $-16M | $-9M | $-5M | $-11M | $-16M | $-4M | |
| Investing Cash Flow | · | $4M | · | · | · | · | |
| Stock Issued | · | · | $1M | · | · | · | |
| Net Stock Activity | · | · | $1M | · | · | · | |
| Financing Cash Flow | $7M | $17M | $1M | $4M | $-97.6K | $33M |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -3609.5% | -18251.7% | -275757.0% | · | |
| Net Margin | · | · | -3509.5% | -18151.7% | -281386.9% | · | |
| Pretax Margin | · | · | -3509.5% | -18151.7% | -281386.9% | · | |
| EBITDA Margin | · | · | -3609.5% | -18251.7% | -275757.0% | · | |
| ROA | -37.1% | -25.1% | -84.5% | -101.4% | -67.6% | · | |
| ROE | -83.8% | 269.2% | -123.6% | -148.0% | -95.6% | · | |
| ROIC | -37.6% | 120.8% | · | · | · | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 5.2 | 11.6 | 8.0 | 12.4 | · | |
| Quick Ratio | 2.1 | 4.7 | 9.3 | 6.7 | 11.0 | · |
效率 1
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.0 | · |
增长率 1
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | 123.6% | 1089.6% | · | · |
估值 (TTM) 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-34M | $-12M | $-5M | $-12M | $-16M | $-10M | |
| Market Cap | $124M | $3M | $277M | $108M | $1.07B | · | |
| P/E | -0.6 | -0.2 | -2.0 | -5.3 | -66.6 | -89.4 | |
| P/B | 1.7 | -0.3 | 72.7 | 14.8 | 73.5 | · | |
| P / Tangible Book | · | · | 72.7 | 14.8 | 73.5 | · | |
| P / Cash Flow | -7.9 | -0.4 | -56.8 | -9.4 | -67.9 | · | |
| Earnings Yield | -171.4% | -502.8% | -49.0% | -18.8% | -1.5% | -1.1% |
损益表 12
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $3M | $3M | $2M | $15M | $3M | $2M | $2M | $535.2K | $336.1K | $343.7K | $298.3K | $374.2K | $557.8K | $497.7K | $1M | $2M | |
| SG&A Expense | $2M | $2M | $1M | $1M | $1M | $2M | $5M | $2M | $733.7K | $970.4K | $839.8K | $900.1K | $919.4K | $1M | $818.0K | $969.9K | |
| Operating Expenses | $14M | $5M | $4M | $16M | $4M | $4M | $8M | $2M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | |
| Operating Income | $-14M | $-5M | $-4M | $-16M | $-4M | $-4M | $-8M | $-2M | $-1M | $-1M | $-1M | $-1M | $-1M | $-2M | $-2M | $-3M | |
| Other Non-op | $53.2K | $90.9K | $57.7K | $63.1K | $115.9K | $-6M | $-186.2K | $20.5K | $20.0K | $22.8K | $35.0K | $39.2K | $36.3K | $40.4K | $45.2K | $16.6K | |
| Pretax Income | $-14M | $-5M | $-4M | $-16M | $-4M | $-11M | $-8M | $-2M | $-1M | $-1M | $-1M | $-1M | $-1M | $-2M | $-2M | $-3M | |
| Net Income | $-12M | $-5M | $-4M | $-16M | $-4M | $-11M | $-8M | $-2M | $-1M | $-1M | $-1M | $-1M | $-1M | $-2M | $-2M | $-3M | |
| EPS (Basic) | $-0.34 | $-0.15 | $11.51 | $-8.20 | $-1.99 | $-8.45 | $-7.64 | $-2.05 | $-1.15 | $-1.68 | $-5.27 | $-1.62 | $-0.08 | $-0.08 | $0.09 | $-0.28 | |
| EPS (Diluted) | $-0.34 | $-0.15 | $11.51 | $-8.20 | $-1.99 | $-8.45 | $-7.64 | $-2.05 | $-1.15 | $-1.68 | $-5.27 | $-1.62 | $-0.08 | $-0.08 | $0.09 | $-0.28 | |
| Shares (Basic) | 34,129,553 | 33,544,748 | -294,650 | 1,919,433 | 1,911,128 | 1,441,535 | -1,768,877 | 1,110,317 | 916,031 | 770,317 | -36,754,468 | 763,750 | 18,411,399 | 18,330,390 | -14,790,619 | 9,199,955 | |
| Shares (Diluted) | 34,129,553 | 33,544,748 | -294,650 | 1,919,433 | 1,911,128 | 1,441,535 | -1,768,877 | 1,110,317 | 916,031 | 770,317 | -36,754,468 | 763,750 | 18,411,399 | 18,330,390 | -14,790,619 | 9,199,955 | |
| EBITDA | $-14M | $-5M | · | $-16M | $-4M | $-4M | · | $-2M | $-1M | $-1M | · | $-1M | $-1M | $-2M | · | $-3M |
资产负债表 24
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $13M | $7M | $10M | $13M | $18M | $15M | $2M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $10M | |
| Prepaid Expense | $1M | $2M | $2M | $2M | $1M | $2M | $2M | $243.4K | $615.7K | $845.1K | $848.5K | $462.8K | $622.0K | $1M | $1M | $1M | |
| Current Assets | $11M | $15M | $8M | $12M | $15M | $19M | $17M | $2M | $4M | $3M | $4M | $5M | $5M | $7M | $8M | $11M | |
| PP&E (Net) | $12.3K | $12.5K | $12.8K | $15.3K | $16.2K | $15.9K | $16.8K | · | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $12.3K | · | $12.8K | $19.0K | $19.4K | $18.4K | $18.4K | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | · | $3.7K | $3.2K | $2.5K | $1.6K | · | · | · | · | · | · | · | · | · | |
| Goodwill | $12M | $12M | $12M | $12M | $12M | $12M | $12M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $57M | $68M | $69M | $68M | $69M | $66M | $66M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $80M | $95M | $90M | $92M | $97M | $97M | $94M | $2M | $4M | $3M | $4M | $5M | $5M | $7M | $8M | $11M | |
| Accounts Payable | $411.5K | $144.4K | $760.9K | $584.6K | $498.1K | $1M | $1M | $455.0K | $217.8K | $196.8K | $111.9K | $205.4K | $214.3K | $135.1K | $573.2K | $679.4K | |
| Accrued Liabilities | $2M | $2M | $2M | $2M | $1M | $1M | $2M | $878.9K | $282.3K | $373.3K | $246.6K | $281.8K | $305.7K | $414.2K | $470.1K | $953.7K | |
| Current Liabilities | $3M | $3M | $3M | $3M | $2M | $3M | $3M | $1M | $500.1K | $570.1K | $358.5K | $487.1K | $520.0K | $549.3K | $1M | $2M | |
| Capital Leases | $69.6K | $87.6K | $105.8K | $120.2K | $132.5K | $140.5K | $154.9K | · | · | · | · | · | · | · | · | · | |
| Deferred Tax | $9M | $12M | $12M | $12M | $12M | $12M | $11M | · | · | · | $0 | · | · | · | $340.9K | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | $15M | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $12M | $15M | $15M | $15M | $14M | $14M | $30M | $1M | $500.1K | $570.1K | $358.5K | $487.1K | $520.0K | $549.3K | $1M | $2M | |
| Common Stock | $3.4K | $3.3K | $3.0K | $229 | $191 | $191 | $133 | $111 | $2.8K | $1.9K | $77 | $1.9K | $1.9K | $1.8K | $1.8K | $1.8K | |
| Paid-in Capital | $196M | $196M | $184M | $73M | $71M | $71M | $68M | $67M | $67M | $66M | $66M | $65M | $64M | $64M | $63M | $63M | |
| Retained Earnings | $-125M | $-113M | $-108M | $-104M | $-89M | $-85M | $-74M | $-66M | $-64M | $-63M | $-61M | $-60M | $-59M | $-58M | $-56M | $-54M | |
| Treasury Stock | $299.1K | $299.1K | $299.1K | $299.1K | $299.1K | $299.1K | $299.1K | $299.1K | $299.1K | $299.1K | $299.1K | $299.1K | $292.2K | · | · | · | |
| AOCI | $-3M | $-2M | $-587.0K | $-2M | $-267.3K | $-4M | $-4M | · | · | · | · | · | · | · | · | · | |
| Stockholders' Equity | $68M | $81M | $75M | $7M | $7M | $7M | $-10M | $949.4K | $3M | $3M | $4M | $5M | $5M | $6M | $7M | $9M | |
| Liabilities + Equity | $80M | $95M | $90M | $92M | $97M | $97M | $94M | $2M | $4M | $3M | $4M | $5M | $5M | $7M | $8M | $11M | |
| Shares Outstanding | 33,629,553 | 33,401,553 | 29,743,516 | 2,293,162 | 1,911,128 | 1,911,128 | 1,332,178 | 1,110,317 | 27,757,937 | 19,257,937 | 770,317 | 19,257,937 | 18,330,390 | 18,330,390 | 18,330,390 | 18,330,390 |
现金流 4
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $543.2K | $449.4K | $157.9K | $48.3K | $65.0K | $84.5K | $93.8K | $94.3K | $148.9K | $139.0K | $148.3K | $148.3K | $161.7K | $161.7K | $149.5K | $164.3K | |
| Deferred Tax | $-2M | $1.2K | $31.8K | $-1.4K | $149 | $190.5K | $-503 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-4M | $-5M | $-4M | $-3M | $-4M | $-5M | $-6M | $-910.1K | $-811.7K | $-937.4K | $-1M | $-960.5K | $-742.4K | $-2M | $-3M | $-2M | |
| Financing Cash Flow | $23 | $11M | $32.6K | $0 | $-120.1K | $7M | $15M | $-70.2K | · | · | $0 | · | · | · | $-86.0K | · |
盈利能力 6
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -5772.2% | · | -3249.5% | -4068.0% | -3852.5% | · | -15611.7% | |
| Net Margin | · | · | · | · | · | · | · | · | · | -5672.2% | · | -3149.5% | -3968.0% | -3752.5% | · | -15511.7% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | -5672.2% | · | -3149.5% | -3968.0% | -3752.5% | · | -15511.7% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -5772.2% | · | -3249.5% | -4068.0% | -3852.5% | · | -15611.7% | |
| ROA | -13.0% | -5.2% | · | -33.4% | -7.6% | -21.8% | · | -60.6% | -16.6% | -30.6% | · | -15.3% | · | -15.9% | · | -16.6% | |
| ROE | -30.6% | -11.4% | · | -383.7% | -76.0% | -224.3% | · | -79.9% | -20.4% | -35.1% | · | -17.7% | · | -18.2% | · | -18.3% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.9 | 5.9 | · | 4.5 | 7.8 | 7.4 | · | 1.7 | 7.3 | 5.7 | · | 10.8 | · | 11.9 | · | 6.6 | |
| Quick Ratio | 3.4 | 5.2 | · | 3.9 | 7.1 | 6.8 | · | 1.5 | 6.0 | 4.2 | · | 9.8 | · | 9.7 | · | 6.0 |
效率 1
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | · | 0.0 | · | 0.0 |
估值 (TTM) 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-36M | $-35M | · | $-33M | $-18M | $-16M | · | $-6M | $-5M | $-5M | · | $-7M | $-9M | $-12M | · | $-14M | |
| Market Cap | $54M | $70M | · | $18M | $9M | $10M | · | $5M | $149M | $231M | · | $445M | · | $169M | · | $175M | |
| P/E | -0.2 | -0.1 | · | -0.4 | -0.3 | -0.4 | · | -0.7 | -1.2 | -3.5 | · | -11.2 | -39.2 | -7.2 | · | -5.6 | |
| P/B | 0.8 | 0.9 | · | 2.4 | 1.3 | 1.4 | · | 5.0 | 47.6 | 86.9 | · | 93.5 | · | 28.2 | · | 18.9 | |
| P / Tangible Book | · | 117.9 | · | · | · | · | · | 5.0 | 47.6 | 86.9 | · | 93.5 | · | 28.2 | · | 18.9 | |
| P / Cash Flow | · | -15.4 | · | · | · | -2.0 | · | · | · | -246.0 | · | · | · | -99.3 | · | · | |
| Earnings Yield | -663.4% | -890.5% | · | -268.7% | -285.9% | -266.1% | · | -152.9% | -84.3% | -28.9% | · | -8.9% | -2.5% | -13.9% | · | -17.7% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 营业利润率 % | — | — | -3609.5% | -18251.7% | -275757.0% |
| 净收入 | $-34M | $-12M | $-5M | $-12M | $-16M |
| 稀释后每股收益 (EPS) | $-7.13 | $-12.52 | $-7.05 | $-1.11 | $-1.92 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 2.8 | 5.2 | 11.6 | 8.0 | 12.4 |
| 速动比率 | 2.1 | 4.7 | 9.3 | 6.7 | 11.0 |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 17 家申报者 · $6.2M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 8 (+4 与上一季度对比) | 3 (+1 与上一季度对比) | 2 (0 与上一季度对比) | 3 (+2 与上一季度对比) | +384K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | $5043302 | 3132486 | 81.60% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $550321 | 341814 | 8.90% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $212768 | 132154 | 3.44% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $122693 | 76206 | 1.99% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $101005 | 62736 | 1.63% | 股份 |
| VANGUARD GROUP INC | $76923 | 18491 | 1.24% | 股份 |
| NORTHERN TRUST CORP | $38284 | 23779 | 0.62% | 股份 |
| CITADEL ADVISORS LLC | $18905 | 11742 | 0.31% | 股份 |
| Tower Research Capital LLC (TRC) | $4980 | 3093 | 0.08% | 股份 |
| MORGAN STANLEY | $3577 | 2222 | 0.06% | 股份 |
| BlackRock, Inc. | $3046 | 1892 | 0.05% | 股份 |
| UBS Group AG | $2995 | 1860 | 0.05% | 股份 |
| MERCER GLOBAL ADVISORS INC /ADV | $886 | 550 | 0.01% | 股份 |
| JONES FINANCIAL COMPANIES LLLP | $264 | 160 | 0.00% | 股份 |
| BARCLAYS PLC | $253 | 157 | 0.00% | 股份 |
| Activest Wealth Management | $193 | 120 | 0.00% | 股份 |
| GROUP ONE TRADING LLC | $14 | 9 | 0.00% | 股份 |
公司内部人士 10 位内幕人士 · 4 位高管 · 7 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Gregory Scott Duncan | Chief Executive Officer | 2021年4月6日 P | 19961 | 0 | 0 | $0 |
| Angela Walsh | VP of Finance | 2021年1月28日 P | 1000 | 0 | 0 | $0 |
| Ralph Grosswald | VP of Finance | 2021年1月11日 A | — | 0 | 0 | $0 |
| Roger Michael Gendreau | Chief Medical Officer | 2021年1月1日 A | — | 0 | 0 | $0 |
| David R Keefer | 董事 | 2026年6月16日 A | 7808 | 0 | 0 | $0 |
| Abel De La Rosa | 董事 | 2026年6月16日 A | — | 0 | 0 | $0 |
| Richard James Whitley | 董事 | 2026年6月16日 A | — | 0 | 0 | $0 |
| John C Thomas | 董事 | 2026年6月16日 A | — | 0 | 0 | $0 |
| CK Life Sciences Int'l., (Holdings) Inc. | 董事 | 2025年3月12日 A | — | 0 | 0 | $0 |
| William Pridgen | 董事 | 2021年1月28日 M | 3500 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Sealbond Limited, CK Life Sciences Int'l., (Holdings) Inc., Conjoint Inc. ×3 申报 | 2025年11月25日 | 83.00% | 修订 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 2 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。